Literature DB >> 33276248

Diagnostic performance of LI-RADS for MRI and CT detection of HCC: A systematic review and diagnostic meta-analysis.

Yingying Liang1, Fan Xu2, Yuan Guo3, Lisha Lai4, Xinqing Jiang5, Xinhua Wei6, Hongzhen Wu7, Jin Wang8.   

Abstract

PURPOSE: To perform a meta-analysis evaluating the diagnostic accuracy of the Liver Imaging Reporting and Data System (LI-RADS) category ≥ 3 (LI-RADS 3-5v) for detecting hepatocellular carcinoma (HCC).
METHOD: A systematic PubMed, Embase, and Web of Science electronic database search was performed for original diagnostic studies published through July 31, 2018. Statistical analysis included data pooling, forest plot construction, heterogeneity testing, meta-regression, and subgroup analyses.
RESULTS: Eighteen studies (v2011, v2014 and v2017) involving 3386 patients were included in the meta-analysis. The pooled sensitivity and specificity of LI-RADS ≥ 3 for diagnosing HCC were 0.86 (95 % confidence interval (CI): 0.78-0.91) and 0.85 (95 % CI: 0.78-0.90), respectively. The area under the curve (AUC) was 0.92 (95 % CI: 0.89-0.94). Meta-regression analysis showed that the publication year, blinding to the reference standard and the number of readers were significant factors affecting heterogeneity. In subgroup analyses, magnetic resonance imaging (MRI) demonstrated higher sensitivity (0.82 vs. 0.73) and comparable specificity (0.79 vs. 0.78) than computed tomography (CT). For HCCs ≤30 mm, LI-RADS showed lower sensitivity of 0.72 and specificity of 0.80 compared with HCC of all sizes. LR-5 showed higher sensitivity and specificity than LR-3 (sensitivity: 0.67 vs. 0.07, P = 0.02; specificity: 0.93 vs. 0.75, p < 0.001) and higher sensitivity than LR-4 (sensitivity: 0.67 vs. 0.29, P = 0.02; specificity: 0.93 vs. 0.80, p = 0.75). LR ≥ 5 had higher specificity at the cost of decreased sensitivity than LR ≥ 3 (specificity: 0.94 vs. 0.68, p < 0.001; sensitivity: 0.66 vs. 0.74, P = 0.70) and LR ≥ 4 (specificity: 0.94 vs. 0.84, p < 0.001; sensitivity: 0.66 vs. 0.74, P = 0.77).
CONCLUSIONS: LI-RADS ≥ 3 shows high diagnostic accuracy for HCCs, with a pooled sensitivity of 0.86 and specificity of 0.85. The specificity is higher for LR-5 and LR ≥ 5. However, further prospective studies on LI-RADS ≥ 3 are needed to elucidate its value for diagnosing small HCCs (≤20 mm).
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Diagnosis; Hepatocellular carcinoma; Meta-analysis; Systematic review

Mesh:

Substances:

Year:  2020        PMID: 33276248     DOI: 10.1016/j.ejrad.2020.109404

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  6 in total

Review 1.  Current and Emerging Tools for Hepatocellular Carcinoma Surveillance.

Authors:  Nia Adeniji; Renumathy Dhanasekaran
Journal:  Hepatol Commun       Date:  2021-09-17

2.  Detection of hepatocellular carcinoma in a population at risk: iodine-enhanced multidetector CT and/or gadoxetic acid-enhanced 3.0 T MRI.

Authors:  Lan Qiong; Zhao Jie; Zheng Zhong; Sheng Wen; Zhao Jun; Lu Liping; Cheng Jinkui
Journal:  BMJ Open       Date:  2022-02-17       Impact factor: 2.692

3.  Risk Stratification and Distribution of Hepatocellular Carcinomas in CEUS and CT/MRI LI-RADS: A Meta-Analysis.

Authors:  Yan Zhou; Zhengyi Qin; Jianmin Ding; Lin Zhao; Ying Chen; Fengmei Wang; Xiang Jing
Journal:  Front Oncol       Date:  2022-03-29       Impact factor: 6.244

Review 4.  Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: Current insights and advancements.

Authors:  Abhilash Perisetti; Hemant Goyal; Rachana Yendala; Ragesh B Thandassery; Emmanouil Giorgakis
Journal:  World J Gastroenterol       Date:  2021-06-28       Impact factor: 5.742

Review 5.  State of the Art in Artificial Intelligence and Radiomics in Hepatocellular Carcinoma.

Authors:  Anna Castaldo; Davide Raffaele De Lucia; Giuseppe Pontillo; Marco Gatti; Sirio Cocozza; Lorenzo Ugga; Renato Cuocolo
Journal:  Diagnostics (Basel)       Date:  2021-06-30

6.  Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit.

Authors:  Alexa Childs; Nekisa Zakeri; Yuk Ting Ma; Joanne O'Rourke; Paul Ross; Essam Hashem; Richard A Hubner; Kimberley Hockenhull; Chinenye Iwuji; Sam Khan; Daniel H Palmer; Joanna Connor; Daniel Swinson; Suzanne Darby; Chiara Braconi; Tom Roques; Dominic Yu; Tu Vinh Luong; Tim Meyer
Journal:  Br J Cancer       Date:  2021-09-15       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.